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Objective: To study the correlation of serum monocyte chemotactant protein-1 (MCP-1)
and vascular endothelia cadherin (VE-cadherin) levels in patients with acute cerebral
infarction, and nerve injury molecules, interleukins and matrix metalloproteinases.
Methods: A total of 86 patients with acute cerebral infarction treated in our hospital from
April 2012 to October 2015 were selected as the observation group and 50 healthy
subjects in the same period treated in our hospital were selected as the control group. The
serums were collected and the contents of MCP-1, VE-cadherin, heart-type fatty acid
binding protein (H-FABP), S100 calcium binding protein B (S100B), neuron-speciﬁc
enolase (NSE), interleukin-lb (IL-1b), IL-6, IL-17, IL-18, matrix metalloproteinase-2
(MMP2), MMP3 and MMP9 were measured.
Results: The serum contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b, IL-
6, IL-17, IL-18, MMP2, MMP3 and MMP9 in observation group were signiﬁcantly
higher than those of control group. Carotid artery plaque formation and unstable plaque
properties will increase the serum contents of MCP-1, VE-cadherin, H-FABP, S100B,
NSE, IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with cerebral
infarction. The serum levels of MCP-1, VE-cadherin and the contents of H-FABP,
S100B, NSE, IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 were positively
correlated.
Conclusions: The serum levels of VE-cadherin and MCP-1 were signiﬁcantly increased
in patients with acute cerebral infarction. MCP-1 and VE-cadherin can increase the
secretion of interleukins and matrix metalloproteinases, which can result in the carotid
artery plaque formation, unstable plaque properties and the injury of nerve function.1. Introduction
Acute cerebral infarction is one of the cardiovascular and ce-
rebrovascular diseases seriously threatening to human health with
high disabling rate and increased morbidity year by year and the
morbidity crowd has a trend of rejuvenation. Cerebral infarction
can cause hypoxic-ischemia necrosis of brain tissue and leave the
varying degrees of dysfunction, which will have a serious impacton patients' daily life and work[1–3]. Thus, how to screen high-risk
groups, early diagnose disease and determine the severity of the
disease has been a hot spot in clinical research. Carotid athero-
sclerosis is an independent risk factor to cause acute cerebral
infarction and inﬂammatory response is an important pathological
change through carotid atherosclerosis in all aspects. After the
vascular endothelium is injured, the inﬂammatory cells will get
into the vascular wall and mediate inﬂammatory response, which
is considered to be the initial step of atherosclerosis[4–6].
Interleukins (ILs) and matrix metalloproteinases (MMPs) are
considered to be the important mediators of inﬂammation
response in the process of mediating carotid atherosclerosis. The
formations of atheromatous plaques and the changes of plaque
characteristics are related to the local inﬁltration of the
inﬂammatory mediators above. Local ischemia and hypoxia
caused by cerebral infarction and the ischemia reperfusion byticle under the CC BY-NC-ND license (http://
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excessive inﬂammatory response of the brain tissue and mediate
the injury of neural function by ILs and MMPs and other
mediators[7–10].
Monocyte chemotactant protein-1 (MCP-1) and vascular
endothelial cadherin (VE-cadherin) are the important molecules
to modulate inﬂammatory cell chemotaxis and adhesion to the
lesion. In the course of the pathology of injury of neural function
after carotid atherosclerosis and cerebral infarction, MCP-1 and
VE-cadherin may be the upstream factor to regulate inﬂamma-
tion response and promote the inﬁltration of inﬂammatory cells
and the release of inﬂammatory mediators[11–14]. However, the
present speciﬁc change of MCP-1 and VE-cadherin in patients
with acute cerebral infarction is not clear. Besides, the correla-
tion between MCP-1, VE-cadherin and the release of inﬂam-
matory mediators and the injury of neural function has not been
reported. In the present study, the serum levels of MCP-1 and
VE-cadherin in patients with acute cerebral infarction and the
correlation with ILs, MMPs and other inﬂammatory mediators
were analyzed.
2. Materials and methods
2.1. Research objects
A total of 86 patients with acute cerebral infarction treated in
our hospital from April 2012 to October 2015 and 50 healthy
subjects treated in our hospital in the same period were selected
to perform prospective study, which was approved by Hospital
Ethics Committee. Patients with acute cerebral infarction were
served as observation group, with the inclusion criteria as fol-
lows: 1. In line with the diagnostic criteria of acute cerebral
infarction in the Fourth National Cerebrovascular Disease
Conference; 2. The onset time not exceeded 72 h and duration
of symptoms for more than 24 h; 3. The brain CT and magnetic
resonance imaging were used to conﬁrm the presence of the
corresponding to the function of cerebral infarction. Patients
with intracerebral hemorrhage, severe heart and lung diseases
or hepatic and kidney function obstacle and patients with his-
tory of infection in nearly one month were excluded. The 50
healthy subjects were served as control group, excluding pa-
tients with a history of acute or chronic inﬂammatory disease
combined with peripheral vascular diseases or thrombotic
disease.
2.2. Evaluation methods of carotid plaques properties
After admission for 1 week, carotid ultrasonography was
undergone with transducer frequency of 7.5 MHz. The detec-
tion range was from carotid artery distal 2.0 cm to internal
carotid artery and external carotid artery proximal 1.0 cm,
measuring the intima-media thickness of multiple parts. Any
side of carotid artery intima-media thickness with more than
1.5 mm was judged as plaque formation, with 1.0–1.5 mm as
the thickening of intima and with less than 1.0 mm as a normal
intima. The parts in the carotid plaque area were scanned
again. If the echo intensity was higher than that of vessel wall,
it was judged as high echo plaques; if uneven, it was judged as
mixed echo plaques; if lower than that of vessel wall and the
plaque highlighted in uterine cavity, it was judged as low echo
plaques.2.3. Evaluation methods of cerebral infarction volume
After admission, emergency CT examination was performed.
The length, width and height of the lesion were measured after
obtaining the images of cerebral infarction lesion and then the
volume of infarction lesion was calculated. The calculating
method was as follows:
Volume of infarction lesion (V, cm3) = length (cm) × width (cm)
× height (cm) × p/6.
V < 5 cm3 was considered as small area infarction, V = 5–
10 cm3 as middle area infarction, V > 10 cm3 as large area
infarction.
2.4. Serum specimen collections and detection methods
Patients in observation group were immediately collected
10 mL peripheral venous blood when admission to the hospital.
The healthy subjects in control group were collected 10 mL
peripheral venous blood when taking physical examination.
After standing at room temperature for 10–15 min, they were
centrifuged for 10 min at 12 000 r/min centrifugal force. Then,
the upper serum was collected and the contents of MCP-1, VE-
cadherin, heart-type fatty acid binding protein (H-FABP), S100
calcium binding protein B (S100B), neuron-speciﬁc enolase
(NSE), IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9
were measured by ELISA kits.
2.5. Statistical methods
The datawere input and analyzed by SPSSversion 19.0 software
and the measurement data were performed by mean ± SD. The an-
alyses between two groups were carried out by t-test and among
three groups by ANOVA. The enumeration data were performed by
frequency form and analyzed by Chi-square test. The correlations
between two variables were veriﬁed by Pearson's correlation anal-
ysis. Differences were statistically signiﬁcant when P < 0.05.
3. Results
3.1. General clinical data of two groups
In observation group, 86 patients included 51 males and 35
females, with (56.30 ± 7.80) years of age, body mass index
(BMI) (23.14 ± 2.97) kg/m2, 53 cases with high blood pressure,
24 cases with diabetes, 45 cases with smoking history. In control
group, 50 patients included 29 males and 21 females, with
(55.80 ± 8.60) years of age, BMI (22.48 ± 2.48) kg/m2, 7 cases
with high blood pressure, 3 cases with diabetes, 14 cases with
smoking history. According to statistic analysis, there were no
differences in sex, age and BMI in two groups, and cases with
high blood pressure, diabetes and smoking history in observa-
tion group were signiﬁcantly higher than those of in control
group (Table 1).
3.2. Comparison of serum biochemical indexes in two
groups
The analyses between two groups on serumbiochemical indexes
of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b, IL-6, IL-
Table 2






MCP-1 (pg/mL) 362.32 ± 42.69 201.46 ± 28.79 < 0.05
VE-cadherin (mg/mL) 6.94 ± 0.89 3.56 ± 0.41 < 0.05
H-FABP (ng/mL) 0.89 ± 0.11 0.26 ± 0.04 < 0.05
S100B (ng/mL) 1.52 ± 0.19 0.42 ± 0.06 < 0.05
NSE (ng/mL) 9.62 ± 1.03 3.36 ± 0.45 < 0.05
IL-1b (ng/mL) 8.59 ± 1.03 2.57 ± 3.41 < 0.05
IL-6 (pg/mL) 19.48 ± 2.67 6.24 ± 0.93 < 0.05
IL-17 (ng/mL) 16.84 ± 2.26 7.46 ± 0.93 < 0.05
IL-18 (pg/mL) 32.58 ± 4.58 14.25 ± 2.16 < 0.05
MMP2 (ng/mL) 83.42 ± 9.51 36.68 ± 5.16 < 0.05
MMP3 (ng/mL) 70.14 ± 8.68 31.24 ± 4.69 < 0.05
MMP9 (ng/mL) 286.56 ± 36.38 116.47 ± 14.57 < 0.05
Data are expressed as mean ± SD.
Table 1






Sex (male/female) 51/35 29/21 > 0.05
Age (years) 56.30 ± 7.80 55.80 ± 8.60 > 0.05
BMI (kg/m2) 23.14 ± 2.97 22.48 ± 2.48 > 0.05
High blood pressure 53 (61.63%) 7 (14.00%) < 0.05
Diabetes 24 (27.91%) 3 (6.00%) < 0.05
Smoking 45 (52.33%) 14 (28.00%) < 0.05
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serum contents of MCP-1 [(362.32 ± 42.69) vs. (201.46 ± 28.79)
pg/mL], VE-cadherin [(6.94 ± 0.89) vs. (3.56 ± 0.41) mg/mL], H-
FABP [(0.89 ± 0.11) vs. (0.26 ± 0.04) ng/mL], S100B [(1.52 ± 0.19)
vs. (0.42 ± 0.06) ng/mL], NSE [(9.62 ± 1.03) vs. (3.36 ± 0.45) ng/
mL], IL-1b [(8.59 ± 1.03) vs. (2.57 ± 3.41) ng/mL, IL-6
[(19.48 ± 2.67) vs. (6.24 ± 0.93) pg/mL], IL-17 [(16.84 ± 2.26)
vs. (7.46 ± 0.93) ng/mL], IL-18 [(32.58 ± 4.58) vs.
(14.25 ± 2.16) pg/mL],MMP2 [(83.42 ± 9.51) vs. (36.68 ± 5.16) ng/
mL, MMP3 [(70.14 ± 8.68) vs. (31.24 ± 4.69) ng/mL], MMP9
[(286.56 ± 36.38) vs. (116.47 ± 14.57) ng/mL] in observation group
were signiﬁcantly higher than those of control group. The differ-
ences on contents of serumMCP-1, VE-cadherin, H-FABP, S100B,Table 3
Serum biochemical indexes in observation group with normal carotid intima
Parameters Patients with normal
carotid intima (n = 17)
Patients wit
thicken
MCP-1 (pg/mL) 282.93 ± 33.51 351.4
VE-cadherin (mg/mL) 4.34 ± 0.61 6.4
H-FABP (ng/mL) 0.44 ± 0.07 0.7
S100B (ng/mL) 0.84 ± 0.11 1.3
NSE (ng/mL) 6.33 ± 0.78 9.3
IL-1b (ng/mL) 5.84 ± 0.71 7.9
IL-6 (pg/mL) 10.33 ± 1.68 17.5
IL-17 (ng/mL) 9.59 ± 1.14 14.6
IL-18 (pg/mL) 22.78 ± 3.47 30.9
MMP2 (ng/mL) 57.94 ± 7.14 79.3
MMP3 (ng/mL) 52.47 ± 6.23 68.6
MMP9 (ng/mL) 193.52 ± 22.57 272.4
Data are expressed as mean ± SD.NSE, IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3 andMMP9 in two
groups were statistical signiﬁcant (P < 0.05) (Table 2).3.3. Comparison of serum biochemical indexes in
cerebral infarction patients with different situation of
carotid plaque
In observation group, the analyses of serum biochemical in-
dexes ofMCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b, IL-
6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with
normal carotid intima, carotid intimal thickening and carotid
intimal plaque formation are shown in Table 3. The serum con-
tents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b, IL-
6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with ca-
rotid intimal thickening and carotid intimal plaque formation were
signiﬁcantly higher than those of patients with normal carotid
intima. The serum contents of MCP-1, VE-cadherin, H-FABP,
S100B, NSE, IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3 and
MMP9 in patients with carotid intimal thickening were signiﬁ-
cantly higher than those of patients with carotid intimal plaque
formation. The differences of the pairwise comparison on serum
contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b,
IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with
normal carotid intima, carotid intimal thickening and carotid
intimal plaque formation were statistical signiﬁcant (P < 0.05).
In observation group, the analyses of serum biochemical
indexes of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-
1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in carotid
plaques patients with high echo plaques, mixed echo plaques
and low echo plaques are shown in Table 4. The contents of
serum MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-1b, IL-
6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients with
mixed echo plaques and low echo plaques were signiﬁcantly
higher than those of patients with high echo plaques. The serum
contents of MCP-1, VE-cadherin, H-FABP, S100B, NSE, IL-
1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in patients
with low echo plaques were signiﬁcantly higher than those of
patients with mixed echo plaques. The differences of the
comparison on serum contents of MCP-1, VE-cadherin, H-
FABP, S100B, NSE, IL-1b, IL-6, IL-17, IL-18, MMP2, MMP3
and MMP9 in patients with high echo plaques, mixed echo
plaques and low echo plaques were statistical signiﬁcant
(P < 0.05)., carotid intimal thickening and carotid intimal plaque formation.
h carotid intimal
ing (n = 29)
Patients with carotid intimal
plaque formation (n = 40)
P
2 ± 37.32 436.48 ± 51.33 < 0.05
2 ± 0.77 8.31 ± 0.98 < 0.05
2 ± 0.09 1.15 ± 0.16 < 0.05
7 ± 0.17 1.94 ± 0.25 < 0.05
1 ± 0.93 12.47 ± 1.74 < 0.05
3 ± 0.93 11.24 ± 1.53 < 0.05
8 ± 2.24 25.67 ± 3.52 < 0.05
8 ± 1.94 21.94 ± 2.94 < 0.05
5 ± 4.28 39.14 ± 5.41 < 0.05
2 ± 8.69 103.48 ± 14.48 < 0.05
5 ± 7.59 93.41 ± 10.35 < 0.05
7 ± 31.38 342.57 ± 41.38 < 0.05
Table 4
Serum biochemical indexes in carotid plaques patients with high echo plaques, mixed echo plaques and low echo plaques.
Parameters High echo plaques (n = 11) Mixed echo plaques (n = 17) Low echo plaques (n = 12) P
MCP-1 (pg/mL) 295.22 ± 32.44 348.75 ± 36.14 430.78 ± 48.27 < 0.05
VE-cadherin (mg/mL) 4.96 ± 0.67 6.15 ± 0.73 8.42 ± 0.93 < 0.05
H-FABP (ng/mL) 0.51 ± 0.08 0.76 ± 0.08 1.02 ± 0.18 < 0.05
S100B (ng/mL) 0.89 ± 0.10 1.32 ± 0.16 1.91 ± 0.23 < 0.05
NSE (ng/mL) 6.14 ± 0.76 9.22 ± 0.99 13.14 ± 1.88 < 0.05
IL-1b (ng/mL) 6.27 ± 0.88 7.68 ± 0.96 11.09 ± 1.37 < 0.05
IL-6 (pg/mL) 9.92 ± 1.22 17.14 ± 2.13 27.24 ± 3.89 < 0.05
IL-17 (ng/mL) 10.13 ± 1.28 15.24 ± 1.78 20.12 ± 2.89 < 0.05
IL-18 (pg/mL) 20.94 ± 3.14 29.34 ± 4.52 42.08 ± 5.77 < 0.05
MMP2 (ng/mL) 54.24 ± 6.89 82.14 ± 9.13 99.24 ± 13.25 < 0.05
MMP3 (ng/mL) 48.17 ± 5.98 66.24 ± 8.13 101.37 ± 15.22 < 0.05
MMP9 (ng/mL) 201.38 ± 25.14 269.35 ± 29.79 351.24 ± 39.22 < 0.05
Data are expressed as mean ± SD.
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Inﬂammatory response is a pathological change of the
various links in the process of atherosclerosis. Many kinds of
inﬂammatory mediators involve in the formation of plaque, the
change of property, the rupture of ﬁbrous cap and the process of
platelet activation and thrombosis. Carotid atherosclerosis is an
independent risk factor to cause cerebral infarction, and plaque
shedding into the brain will result in arterial embolism, blood
ﬂow interruption and ischemic injury of neurological function.
While ischemia reperfusion caused by thrombolysis or inter-
ventional therapy will further activate the local excessive in-
ﬂammatory response of the brain tissue, and then continue to
cause injury of neural function through the inﬂammatory me-
diators[15,16]. In this study, the analyses of MCP-1 and VE-
cadherin were important molecules to regulate the inﬂamma-
tory cells in local lesions inﬁltration. MCP-1 is a member of the
CC family of chemokines, which can promote the migration
from mononuclear macrophages to the arterial intima and form
foam cells, thereby accelerating the formation of atheromatous
plaques[17,18]. VE-cadherin is a member of the family of E-cad-
herin, which connected with intracellular protein b-catenin
through the end of carbon and transferred biological signals
promoting the secretion of a variety of inﬂammatory factors[19].
The above research analyses have conﬁrmed that the serum
contents of MCP-1 and VE-cadherin in patients with cerebral
infarction were signiﬁcantly increased, which indicated that the
increase of contents of MCP-1 and VE-cadherin is related to
cerebral infarction.
Cerebral infarction will lead to the multiple molecules like H-
FABP, S100B, NSE and other molecules in neurocyte releasing
into the cerebrospinal ﬂuid, thereby only the blood brain barrier
getting into blood circulation. The contents of serum marker
molecules H-FABP, S100B and NSE were detected to reﬂect the
degree of nerve injury of cerebral infarction. H-FABP is a member
of family of FABP participating in the transport andmetabolism of
fatty acids in the body and positioning in endochylema of nerve
cells. S100B is a kind of acidic calcium binding protein highly
expressed in neuron which can promote axonal growth and
neuronal differentiation[20,21]. NSE is a kind of enolization dimer
enzyme isozyme in neuron participating in the regulation of
cellular energy metabolism[22,23]. Hypoxic-ischemia injury caused
by cerebral infarction can lead to H-FABP, S100B and NSE get-
ting into the blood circulation. The analyses of molecular contents
in serum above conﬁrmed that the serum contents of H-FABP,S100B and NSE in patients with cerebral infarction were signiﬁ-
cantly higher than those in healthy subjects with physical exami-
nation and positively related with the serum contents of MCP-1
and VE-cadherin. This suggested that the increase of contents of
MCP-1 and VE-cadherin is related to the injury of neural function
in patients with cerebral infarction. MCP-1 and VE-cadherin may
cause nerve cell damage and the injury of neural function through
mediating inﬂammatory response of infarction lesions.
Carotid atherosclerosis is an independent risk factor to cause
cerebral infarction. Further analyses of the relationship of contents
between carotid atherosclerosis and MCP-1 and VE-cadherin can
get to know that the increase of contents of MCP-1 and VE-
cadherin will form carotid artery plaque and change the property
of plaque, which indicated that the increase of contents of MCP-1
and VE-cadherin not only participates in nerve cell damage, but
also involves the formation of carotid artery plaque and the change
of property. ILs and MMPs are the important mediators to mediate
carotid atherosclerosis. IL-1b, IL-6, IL-17 and IL-18 are inter-
leukinmolecules with proinﬂammatory effects, which can not only
lead to the trend from neutrophile granulocyte to carotid intimal
and promote the formation of atheromatous plaque, but also inﬁl-
trate in atherosclerotic lesions and cause nerve cell damage[24–27].
MMP2, MMP3 and MMP9 play a role in degrading extracellular
matrix. MMP in atheromatous plaque can degrade ﬁbrous cap
and cause the rupture of plaque and the change of property.
MMP in the parts of brain ischemia and the ischemia reperfusion
can damage the blood brain barrier and cause brain edema[28,29].
The analyses of the serum contents of ILs and MMPs in patients
with cerebral infarction conﬁrmed that the serum contents of IL-
1b, IL-6, IL-17, IL-18, MMP2, MMP3 and MMP9 in observa-
tion groupwere signiﬁcantly higher than those of control group and
positively related with MCP-1 and VE-cadherin, which indicated
thatMCP-1 andVE-cadherin can promote the secretion of a variety
of ILs and MMPs.
In conclusion, the serum levels of MCP-1 and VE-cadherin
was signiﬁcantly increased in patients with acute cerebral
infarction. VE-cadherin and MCP-1 can increase the secretion
of ILs and MMPs, which can result in the carotid artery
plaque formation, unstable properties and the injury of nerve
function.Conﬂict of interest statement
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